Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients

Fig. 2

Progression-free survival (PFS) after cabazitaxel treatment. a PFS in the all-patient cohort (median survival 2.8 months, 95% CI 1.9–4.4). b PFS in the patients with the high initial CBZ dose (high-dose) group (median survival 2.1 months, 95% CI 1.2–5.5) and with the low initial CBZ dose (low-dose) group (median survival 3.0 months, 95% CI 2.0–4.4). P = 0.904 by log-rank test

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us